Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A1YQ
|
|||
| Former ID |
DNC001296
|
|||
| Drug Name |
SB216763
|
|||
| Synonyms |
280744-09-4; SB 216763; 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; SB216763; SB-216763; 3-(2,4-dichlorophenyl)-4-(1-methylindol-3-yl)pyrrole-2,5-dione; 1H-Pyrrole-2,5-dione, 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-; CHEMBL102714; 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; SR-01000076052; Tocris-1616; Lopac-S-3442; AC1L41YI; Lopac0_000934; SCHEMBL30251; MLS001074894; cid_176158; BDBM8296; GTPL8015; CTK8B4807; CHEBI:91421; AOB5004; SYN1075; EX-A291
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H12Cl2N2O2
|
|||
| Canonical SMILES |
CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl
|
|||
| InChI |
1S/C19H12Cl2N2O2/c1-23-9-13(11-4-2-3-5-15(11)23)17-16(18(24)22-19(17)25)12-7-6-10(20)8-14(12)21/h2-9H,1H3,(H,22,24,25)
|
|||
| InChIKey |
JCSGFHVFHSKIJH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 280744-09-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7343520, 10258353, 11109049, 11111799, 11114153, 14804046, 17405492, 24278616, 33499834, 47425384, 49674819, 50069836, 50104912, 50104913, 53778040, 53788992, 57395289, 68529953, 76969976, 85231225, 85789038, 90341064, 91746567, 92304118, 99436968, 103321785, 104425367, 110522903, 121361674, 124659174, 124756979, 124801217, 124881439, 124881440, 125163784, 125335564, 126666960, 128256156, 131308731, 131480748, 134341362, 134964391, 135154100, 135314161, 135685334, 135685335, 135685354, 135697689, 136340311, 136367277
|
|||
| ChEBI ID |
CHEBI:91421
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Target Info | Inhibitor | [2], [3], [4] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Insulin/IGF pathway-protein kinase B signaling cascade | ||||
| PDGF signaling pathway | ||||
| Ras Pathway | ||||
| Pathway Interaction Database | Degradation of beta catenin | |||
| Canonical Wnt signaling pathway | ||||
| FOXM1 transcription factor network | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| Reactome | AKT phosphorylates targets in the cytosol | |||
| XBP1(S) activates chaperone genes | ||||
| Constitutive Signaling by AKT1 E17K in Cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8015). | |||
| REF 2 | Intracellular protein phosphorylation in eosinophils and the functional relevance in cytokine production. Int Arch Allergy Immunol. 2009;149 Suppl 1:45-50. | |||
| REF 3 | Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology. 2009 Jun;56(8):1116-23. | |||
| REF 4 | The ceiling effect of pharmacological postconditioning with the phytoestrogen genistein is reversed by the GSK3beta inhibitor SB 216763 [3-(2,4-dic... J Pharmacol Exp Ther. 2009 Jun;329(3):1134-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.